m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00388)
Target Name Stearoyl-CoA desaturase (SCD)
Synonyms
hSCD1; Acyl-CoA desaturase; Delta(9)-desaturase; Delta-9 desaturase; Fatty acid desaturase; FADS5; SCD1; SCDOS
    Click to Show/Hide
Gene Name SCD
Chromosomal Location 10q24.31
Family fatty acid desaturase type 1 family
Function
Stearoyl-CoA desaturase that utilizes O(2) and electrons from reduced cytochrome b5 to introduce the first double bond into saturated fatty acyl-CoA substrates. Catalyzes the insertion of a cis double bond at the delta-9 position into fatty acyl-CoA substrates including palmitoyl-CoA and stearoyl-CoA. Gives rise to a mixture of 16:1 and 18:1 unsaturated fatty acids. Plays an important role in lipid biosynthesis. Plays an important role in regulating the expression of genes that are involved in lipogenesis and in regulating mitochondrial fatty acid oxidation (By similarity). Plays an important role in body energy homeostasis (By similarity). Contributes to the biosynthesis of membrane phospholipids, cholesterol esters and triglycerides (By similarity).
    Click to Show/Hide
Gene ID 6319
Uniprot ID
SCD_HUMAN
HGNC ID
HGNC:10571
Ensembl Gene ID
ENSG00000099194
KEGG ID
hsa:6319
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
SCD can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line MDA-MB-231 Homo sapiens
Treatment: METTL3 knockdown MDA-MB-231 cells
Control: MDA-MB-231 cells
 GSE70061
Regulation
logFC: -1.10E+00
p-value: 2.11E-02
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between SCD and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 1.17E+00 GSE60213
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Targeting METTL3/14 in vitro increases protein level of ACLY and Stearoyl-CoA desaturase (SCD) as well as triglyceride and cholesterol production and accumulation of lipid droplets. These findings demonstrate a new NAFLD mouse model that provides a study platform for DM2-related NAFLD and reveals a unique epitranscriptional regulating mechanism for lipid metabolism via m6A-modified protein expression of ACLY and SCD1.
Target Regulation Up regulation
Responsed Disease Non-alcoholic fatty liver disease ICD-11: DB92
 Disease Info 
Pathway Response Glycerolipid metabolism hsa00561
Cell Process Lipid metabolism
In-vitro Model LM3 Malignant neoplasms Mus musculus CVCL_D269
MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
In-vivo Model Mice with a Tmem30a deletion specifically in pancreatic beta cells were generated as previously described. Mice developed with NAFLD were named for Tmem30a-associated NAFLD (TAN) mice. The littermate mice with genotypes of Tmem30aloxP/loxP were used as controls.
Methyltransferase-like 14 (METTL14) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14
Cell Line HepG2 cell line Homo sapiens
Treatment: shMETTL14 HepG2 cells
Control: shCtrl HepG2 cells
 GSE121949
Regulation
logFC: 1.25E+00
p-value: 7.56E-25
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Targeting METTL3/14 in vitro increases protein level of ACLY and Stearoyl-CoA desaturase (SCD) as well as triglyceride and cholesterol production and accumulation of lipid droplets. These findings demonstrate a new NAFLD mouse model that provides a study platform for DM2-related NAFLD and reveals a unique epitranscriptional regulating mechanism for lipid metabolism via m6A-modified protein expression of ACLY and SCD1.
Target Regulation Up regulation
Responsed Disease Non-alcoholic fatty liver disease ICD-11: DB92
 Disease Info 
Pathway Response Glycerolipid metabolism hsa00561
Cell Process Lipid metabolism
In-vitro Model LM3 Malignant neoplasms Mus musculus CVCL_D269
MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
In-vivo Model Mice with a Tmem30a deletion specifically in pancreatic beta cells were generated as previously described. Mice developed with NAFLD were named for Tmem30a-associated NAFLD (TAN) mice. The littermate mice with genotypes of Tmem30aloxP/loxP were used as controls.
YTH domain-containing protein 2 (YTHDC2) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary In nonalcoholic fatty liver disease, Ythdc2 could bind to mRNA of lipogenic genes, including sterol regulatory element-binding protein 1c, fatty acid synthase, Stearoyl-CoA desaturase (SCD), and acetyl-CoA carboxylase 1, to decrease their mRNA stability and inhibit gene expression.
Target Regulation Down regulation
Responsed Disease Non-alcoholic fatty liver disease ICD-11: DB92
 Disease Info 
Pathway Response RNA degradation hsa03018
Cell Process RNA stability
In-vivo Model All mice were housed at 21℃ ± 1℃ with a humidity of 55% ± 10% and a 12-hour light/dark cycle. The high-fat diets (HFDs), containing 60% kcal from fat, 20% kcal from carbohydrate, and 20% kcal from protein.
Non-alcoholic fatty liver disease [ICD-11: DB92]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Targeting METTL3/14 in vitro increases protein level of ACLY and Stearoyl-CoA desaturase (SCD) as well as triglyceride and cholesterol production and accumulation of lipid droplets. These findings demonstrate a new NAFLD mouse model that provides a study platform for DM2-related NAFLD and reveals a unique epitranscriptional regulating mechanism for lipid metabolism via m6A-modified protein expression of ACLY and SCD1.
Responsed Disease Non-alcoholic fatty liver disease [ICD-11: DB92]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Glycerolipid metabolism hsa00561
Cell Process Lipid metabolism
In-vitro Model LM3 Malignant neoplasms Mus musculus CVCL_D269
MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
In-vivo Model Mice with a Tmem30a deletion specifically in pancreatic beta cells were generated as previously described. Mice developed with NAFLD were named for Tmem30a-associated NAFLD (TAN) mice. The littermate mice with genotypes of Tmem30aloxP/loxP were used as controls.
Experiment 2 Reporting the m6A-centered Disease Response [2]
Response Summary In nonalcoholic fatty liver disease, Ythdc2 could bind to mRNA of lipogenic genes, including sterol regulatory element-binding protein 1c, fatty acid synthase, Stearoyl-CoA desaturase (SCD), and acetyl-CoA carboxylase 1, to decrease their mRNA stability and inhibit gene expression.
Responsed Disease Non-alcoholic fatty liver disease [ICD-11: DB92]
Target Regulator YTH domain-containing protein 2 (YTHDC2) READER
 Regulator Info 
Target Regulation Down regulation
Pathway Response RNA degradation hsa03018
Cell Process RNA stability
In-vivo Model All mice were housed at 21℃ ± 1℃ with a humidity of 55% ± 10% and a 12-hour light/dark cycle. The high-fat diets (HFDs), containing 60% kcal from fat, 20% kcal from carbohydrate, and 20% kcal from protein.
References
Ref 1 Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. Mol Ther. 2022 Jun 1;30(6):2342-2353. doi: 10.1016/j.ymthe.2022.02.021. Epub 2022 Feb 19.
Ref 2 N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes. Hepatology. 2021 Jan;73(1):91-103. doi: 10.1002/hep.31220. Epub 2020 Oct 25.